Quick look 39: DCGI approves Covishield, Covaxin Covid-19 vaccines for emergency use

Siddharth Mathew Cherian | Updated on January 03, 2021 Published on January 03, 2021

India's drugs regulator has approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute of India, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country on Sunday, paving the way for a massive inoculation drive.

The Drugs Controller General of India (DCGI) granted the approval on the basis of recommendations by a COVID-19 Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).

Prime Minister Narendra Modi hailed the approval as a "decisive turning point" in the spirited fight against the pandemic. He added that this would accelerate the process for India to become a COVID-free nation.

He extended his gratitude to doctors, medical staff, scientists, police personnel, sanitation workers, and all ''Corona warriors'' for the outstanding work they have done in adverse circumstances, and said the nation will remain eternally grateful to them for saving many lives.

India's Covid-19 active caseload has dropped below 2.5 lakh today, with the recoveries exceeding new cases and the low number of fatalities per day.

India's present active caseload consists of just 2.39 per cent of India's Total Positive Cases. The total coronavirus cases are at 1,03,23,965 and the death toll climbed to 1,49,435 with Covid-19 claiming 217 lives in a span of the last 24 hours.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on January 03, 2021